Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.
Splice Bio has raised $135.0M in total funding. The most recent round was Series B. The last funding was announced in June 2025.
Splice Bio's investors include New Enterprise Associates, EQT Life Sciences, Ysios Capital, Asabys Partners, Gilde Healthcare.
Splice Bio is headquartered in Barcelona, Spain.
Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.
Splice Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Splice Bio — Funding & Investors." VCBacked, June 11, 2025, https://www.vcbacked.co/company/splice-bio. Accessed September 3, 2026.
VCBacked. (2025). Splice Bio — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/splice-bio
{{cite web |title=Splice Bio — Funding & Investors |url=https://www.vcbacked.co/company/splice-bio |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated